ethyl 4-bromo-2-(hydroxyamino)-3-(2,3,4-trimethoxyphenyl)-3H-pyrrole-5-carboxylate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 4-bromo-2-(hydroxyamino)-3-(2,3,4-trimethoxyphenyl)-3H-pyrrole-5-carboxylate
• 化学式: C₁₆H₁₉BrN₂O₆
• 分子量: 415.24
• InChiKey: DIIPTUMZLMKKBR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  98.6
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• [EN] TARGETED THERAPEUTICS<br/>[FR] THÉRAPEUTIQUE CIBLÉE
  申请人：SYNTA PHARMACEUTICALS CORP

  公开号：WO2015038649A1

  公开（公告）日：2015-03-19

  The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.

  本发明提供了包括与将效应子导向至感兴趣的生物靶点的结合基团共轭的药理化合物。同样，本发明提供了包括这些化合物的组合物、试剂盒和方法（例如治疗、诊断和成像）。这些化合物可以被描述为蛋白质相互作用结合基团-药物共轭（SDC-TRAP）化合物，其中包括蛋白质相互作用结合基团和效应子。例如，在针对治疗癌症的某些实施方式中，SDC-TRAP可以包括Hsp90抑制剂共轭到细胞毒性药剂作为效应子。
• [EN] POLYSUBSTITUTED PYRROLES HAVING MICROTUBULE-DISRUPTING, CYTOTOXIC AND ANTITUMOR ACTIVITIES AND METHDS OF USE THEREOF<br/>[FR] PYRROLES POLYSUBSTITUÉS AYANT DES ACTIVITÉS DE RUPTURE DE MICROTUBULES, CYTOTOXIQUES ET ANTITUMORALES ET MÉTHODES LES UTILISANT
  申请人：KELLOGG GLEN E

  公开号：WO2015039073A1

  公开（公告）日：2015-03-19

  The present invention provides polysubstituted pyrrole compounds, pharmaceutically effective salts, prodrugs, solvates and hydrates thereof, having antimitotic, antiproliferative and cytotoxic activity, activity against cells expressing the drug efflux protein, P-glycoprotein, or cells expressing the β-ΙΙΙ isotype of tubulin and antitumor activity. Also provided are methods of utilizing these compounds for inhibiting the proliferation of cancer cells as well as their medical use, in particular for treating cancer, including drug resistant cancer.

  本发明提供了多取代吡咯化合物，药效盐、前药、溶剂合物和水合物，具有抗有丝分裂、抗增殖和细胞毒活性，对表达药物外流蛋白P-糖蛋白的细胞、或表达β-ΙΙΙ微管蛋白亚型的细胞具有活性，并具有抗肿瘤活性。还提供了利用这些化合物抑制癌细胞增殖的方法，以及它们的医疗用途，特别是用于治疗癌症，包括耐药性癌症。
• TARGETED THERAPEUTICS
  申请人：Synta Pharmaceuticals Corp.

  公开号：EP3035938A1

  公开（公告）日：2016-06-29
• POLYSUBSTITUTED PYRROLES HAVING MICROTUBULE-DISRUPTING, CYTOTOXIC AND ANTITUMOR ACTIVITIES AND METHODS OF USE THEREOF
  申请人：KELLOGG Glen E.

  公开号：US20160297757A1

  公开（公告）日：2016-10-13

  The present invention provides polysubstituted pyrrole compounds, pharmaceutically effective salts, prodrugs, solvates and hydrates thereof, having antimitotic, antiproliferative and cytotoxic activity, activity against cells expressing the drug efflux protein, P-glycoprotein, or cells expressing the β-III isotype of tubulin and antitumor activity. Also provided are methods of utilizing these compounds for inhibiting the proliferation of cancer cells as well as their medical use, in particular for treating cancer, including drug resistant cancer.
• US9944597B2
  申请人：——

  公开号：US9944597B2

  公开（公告）日：2018-04-17